Ocugen releases presentation with clinical data showing treatment benefit in retinal disease studies

Ocugen, Inc.

Presentation shows mean change in total atrophy area from baseline reduced by 84% in treated group (0.12 mm²) vs untreated (0.73 mm²).
Visual acuity improvement in treated eyes across multiple cohorts (006-001, 007-001, 006-004) compared to untreated.
Treated mutant group shows better outcomes than untreated mutant in LL VA change over 6 months.
Presentation posted on company website December 3, 2024 and may be used in investor discussions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.